|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
β-Catenin, a core component of Wnt/β-catenin signaling, has been shown to be a crucial factor in a broad range of tumors, while its role in glioma is not well understood.
|
20300972 |
2011 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Accordingly, we aimed to investigate NCTD as an anti-neoplastic drug that inhibits the Wnt/β‑catenin pathway via promoter demethylation of Wnt inhibitory factor-1 (WIF-1) in glioma growth in vitro.
|
26781164 |
2016 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although aberrant nuclear accumulation of β-catenin is linked to the malignant progression of gliomas, its association with IDH1 remains unknown.
|
26860959 |
2016 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Analysis of clinical specimens verified a positive correlation between Fra1 and β-catenin as well as a poor prognosis in glioma patients with double-high expressions of them.
|
28232512 |
2017 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
As we demonstrated earlier that α5β1 integrin may be considered as a therapeutic target in high grade glioma through its contribution to glioma cell migration and resistance to chemotherapy, we addressed here the potential relationship between α5β1 integrin and beta-catenin activation in glioma cells.
|
27613837 |
2016 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Astrocyte Elevated Gene-1 Regulates β-Catenin Signaling to Maintain Glioma Stem-like Stemness and Self-Renewal.
|
27903708 |
2017 |
|
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
AURKA governs self-renewal capacity in glioma-initiating cells via stabilization/activation of β-catenin/Wnt signaling.
|
23761169 |
2013 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CBX7 negatively regulates migration and invasion in glioma via Wnt/β-catenin pathway inactivation.
|
28388562 |
2017 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CONCLUSIONS In human glioma cell lines, silencing the MYH10 gene reduced cell migration and invasion, by inhibiting the Wnt/β-catenin pathway, which may regulate the ECM and inhibit EMT in human glioma.
|
30552850 |
2018 |
|
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Consistently, MAGI3 overexpression in glioma cells C6 suppressed expression of β-catenin target genes including Cyclin D1 and Axin2, whereas MAGI3 knockdown in glioma cells U373 and LN229 enhanced their expression.
|
26452219 |
2015 |
|
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Contrarily, SND1 and β-catenin expressions were positively correlated with glioma grades and Ki-67 index, but inversely correlated with miR-320a expression and patients' survival.
|
28160566 |
2017 |
|
Glioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Cytokines related to glioma risk (P ≤ .05) more than 10 years before diagnosis are sIL10RB, VEGF, beta-Catenin and CCL22.
|
28594935 |
2017 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Down-regulation of USP9X also consistently inhibits the tumorigenicity of primary glioma cells in vivo.In summary, these results indicate that USP9X stabilizes β-catenin and activates Wnt/β-catenin signal pathway to promote glioma cell proliferation and survival.
|
27783990 |
2016 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Due to its capacity to counteract β-catenin and glioma cell proliferation and migration, pioglitazone represents a promising drug for adjuvant therapy of glioma and other highly migratory tumor entities.
|
21221726 |
2011 |
|
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Expression of WNT3a, cytoplasmic β-catenin and TCF4 was significantly associated with the histological malignancy grade and with a worse prognosis for patients with glioma.
|
26708597 |
2016 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
FOXK1 promotes cell growth through activating wnt/β-catenin pathway and emerges as a novel target of miR-137 in glioma.
|
30018719 |
2018 |
|
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, Eps8 modulated the levels of phosphorylated extracellular signal-regulated protein kinase (ERK), phosphorylated serine-threonine protein kinase Akt and β-catenin expression in glioma cell lines and tissues.
|
23229386 |
2013 |
|
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, eIF4FD suppressed glioma vascularization via reductions in the expression of β‑catenin and vascular endothelial growth factor.
|
30066885 |
2018 |
|
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, HDAC4 overexpression was revealed to substantially inhibit the expression of cyclin-dependent kinase (CDK) inhibitors p21 and p27, and the expression of E-cadherin and β‑catenin in glioma U251 cells.
|
30272277 |
2018 |
|
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Glucocorticoid receptor β regulates injury-mediated astrocyte activation and contributes to glioma pathogenesis via modulation of β-catenin/TCF transcriptional activity.
|
23906498 |
2013 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Gold quantum dots impair the tumorigenic potential of glioma stem-like cells via β-catenin downregulation in vitro.
|
30863050 |
2019 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we studied phosphoY142 (PY142) β-catenin and dephospho S/T β-catenin (a classical Wnt transducer) in glioma biopsies, GBM cell lines and biopsy-derived glioma cell cultures.
|
26654598 |
2015 |
|
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Importantly, silencing β-catenin recapitulated the cellular and molecular effects seen upon miR-188 overexpression, which included inhibiting glioma cell proliferation and G1-S transition.
|
29268818 |
2018 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, our study suggests that SPOCK1 promotes proliferation, migration and invasion in glioma cells by activating PI3K/AKT and Wnt/β-catenin pathways, which provides a potential theoretical basis for clinical treatment of glioma.
|
27108836 |
2016 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, our study validates a pathogenetic role of miR-19 in glioma and establishes a potentially regulatory and signaling involving miR-19 /RUNX3/β-catenin, also suggesting miR-19 may be a candidate therapeutic target in glioma.
|
29340016 |
2017 |